Remove Collective Remove Conditions Remove Data Remove Reference
article thumbnail

Could CBN really help you sleep? Consumer study data suggest yes.

The Cannigma

MoreBetter, creators of the Releaf App, is using this real world data to push back against the claim that there’s no evidence that CBN can help people sleep. In September 2021, MoreBetter hosted a self-reported data collection with this CBN tincture offered to participants for free of charge from CBDistillery. Back to our study.

Sleep 133
article thumbnail

Papa’s Herb® Enters the Oregon Market Through Halo Collective

Cannabis Law Report

TORONTO , July 19, 2021 /CNW/ – Halo Collective Inc. (“Halo” or the “Company”) (NEO: HALO) (OTCQX: HCANF) (Germany: A9KN), a vertically integrated cannabis company, announced today that it has entered into a brand licensing arrangement (the “Licensing Agreement”) with Brezwald Corp.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Medxtractor Doubles Down on B2B Licensing & mHealth

Cannabis Law Report

(CSE: MXT) (OTCQB: MXTTF) aims to address these problems by pairing biometric interviews with brainwave data to create a proprietary mental health reference database. Using machine learning algorithms and qualified practitioner input, the company is leveraging that data to build tools that deliver digital diagnostic opinions.

article thumbnail

RYAH Medtech Inc. Completes Initial Shipment for Major UK-based Clinical Trial

Cannabis Law Report

Given the size and scale of the study, RYAH has developed a custom software solution, using OAuth API-integration to protect the privacy of the participants in the study, with the goal of enabling a fully integrated, patient feedback and data collection capability. About RYAH Group, Inc. RYAH Group, Inc.

article thumbnail

Phase 1 Clinical Trial Data Indicate IGC’s THC-based Investigational New Drug May Reduce Symptoms of Dementia in Alzheimer’s Patients

Cannabis Law Report

The results of the clinical trial have been submitted in the Clinical/Statistical Report (“CSR”) filed with the FDA, and relevant data is also available on Form 8-K filed with the SEC on December 2, 2021. Alzheimer’s disease impacts about 50 million people worldwide and about 5.5 million individuals in the U.S.

article thumbnail

New Study Shows How Microdosing Psychedelics Can Enhance Your Innate Self-Expression

Veriheal

The research, recently published in the respected journal Nordic Studies on Alcohol and Drugs, examined the complex relationship between microdosing and what’s referred to as a ‘state of authenticity’ – the feeling of being truly genuine and honest with oneself in a given moment.

article thumbnail

Clinical Trial on Alzheimer’s Patients Indicates Positive Safety and Tolerability Data for IGC’s THC-Based Investigational New Drug

Cannabis Law Report

(“IGC” or the “Company”) today announced positive primary endpoint data for its Phase 1 clinical trial for IGC-AD1, which is a proprietary cannabinoid-based investigational new drug candidate for patients who have Alzheimer’s disease. Food and Drug Administration (FDA) on December 1, 2021.